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Today prostatic adenocarcinoma is the most commonly di- 
agnosed malignancy in men. Organ confined tumor is curable 
but once metastasis occurs tumor progression can only be 
delayed temporarily. 160 
CASE REPORT 
A 59-year-old man originally presented with T3 pT3NlMO 
grade 2 prostatic adenocarcinoma after radical retmpubic pros- 
tatectomy. After 9 years he underwent surgical castration for a 
painful solitary metastatic lesion in the right pelvis, confirmed 
by highly elevated prostatic acid phosphatase and prostate spe- 
cific antigen (PSA), and a new metastasis seen on a bone scan of 
the right 0s ischium. Palliative irradiation was given 2 years 
later due to increasing pain and confirmed histological evidence 
of metastatic prostatic adencarcinoma tissue by bone biopsy 
(fig. 1). (The Tandem-E PSA assay was used before January 
1993 and the Abbott IMx assay was used thereafter.) PSA 
increased dramatically 1 year later without clinical signs of 
local recurrence or new metastatic lesions. Subsequently PSA 
suddenly and unexpectedly decreased (fig. 2). Presently PSA 
has been stable at  0.4 MA. (normal 0 to 4) for 12 months and 
the metastasis seen on the bone scan has completely disap 
peared. 
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DISCUSSION 
20 Even when values are within the normal range, increasing 
PSA in 6 to 12 months in a hormone treated pkient signal; 
clinical progression for 80 to 85% of this population.' six 
years after surgical castration and 4 years aRer palliative 
irradiation PSA increased in our case, indicating progressive 
disease. The sudden decrease in PSA and complete disap- 
pearance of the metastasis from the bone scan cannot be 
explained by previous medical intervention. Remission of 
metastatic lesions after treatment of the primary prostatic 
tumor due to a cryosurgically induced immune response has 
Accepted for publication July 21, 1995. 
1978 1980 19R2 1984 1986 1988 1990 1992 1994 1996 
time (years) 
FIG. 2. Fluctuation of serum PSA, serum prostatic acid phos- 
phatase (PAP) and serum testosterone with time. Increase in PSA 
was not paralleled by serum testosterone increase, excluding surrep- 
titious testosterone intake as caw of this phenomenon. Note time of 
surgical castration in August 1988 (arrowhead) and palliative irra- 
rliatinn in June 1990 (arrowhead). PSA determinations were re- 
been previously reported.2 Repeat PSA determinations with 
4 kits (Hybritech, Boehringer, Wallace and Abbott) were not 
significantly different (fig. 2). Hyperglobulinemia, human an- 
ti-mouse antibodies or other heterophilic antibodies were 
unlikely to be responsible for detection errors.1.3 A literature 
search from 1966 to December 1994 did not reveal a similar 
case. Therefore, we believe that our report represents the 
first case of spontaneous remission of a bony metastasis of 
prostatic adenocarcinoma. 
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